Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients-Reference-Cited by-同舟云学术

Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients

Published:2020-10-20 Issue:1 Volume:30 Page:
ISSN:2055-1010
Container-title:npj Primary Care Respiratory Medicine
language:en
Short-container-title:npj Prim. Care Respir. Med.

Author:

Ställberg Björn^ORCID,Janson Christer,Lisspers Karin,Johansson Gunnar,Gutzwiller Florian S.^ORCID,Mezzi Karen,Bjerregaard Bine Kjoeller^ORCID,Kejs Anne Mette Tranberg,Jorgensen Leif,Larsson Kjell

Abstract

AbstractThis study reports the association of ICS use and the risk of type 2 diabetes mellitus (T2DM) in Swedish patients with COPD using data from real-world, primary care settings. A total of 7078 patients with COPD were included in this analysis and the 5-year cumulative incidence rate per 100,000 person years was 1506.9. The yearly incidence rate per 100,000 person years ranged from 850 to 1919. Use of ICS especially at a high dose in patients with COPD was related to an increased risk of T2DM.

Funder

Novartis

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine

Link

https://www.nature.com/articles/s41533-020-00207-7.pdf

Reference15 articles.

1. Mannino, D. M., Thorn, D., Swensen, A. & Holguin, F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur. Respir. J. 32, 962–969 (2008).

2. Price, D. B. et al. Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study. NPJ Prim. Care Respir. Med. 29, 38 (2019).

3. Rana, J. S. et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 27, 2478–2484 (2004).